The CenterWatch Monthly, August 2017
Fastest drug developers and their practices
Drug development is a long and costly process, and companies struggle with efforts to compress cycle times and reduce costs. A new CenterWatch analysis of new molecular entities (NMEs) approved by the FDA from 2014 through 2016 shows no signs of dramatic, industry-wide improvement. Sponsors interviewed by CenterWatch cited multiple factors that influence the speed of their development programs. In particular, the selection of investigative sites and vendors (including CROs), and the relationships forged with them, were an important focus of companies seeking to improve the speed and efficiency of clinical trials.
Preparing sites for post-acquisition integration
The seemingly endless number of tasks required to sell a clinical research site often means there isn’t enough attention focused on what happens after the deal closes. Successful post-acquisition integration can be one of the most challenging, yet important, parts of an M&A process. Buyers typically want the site owner or key principal investigator (PI) to stay with the company for two or three years after the transaction to help lead integration activities and grow the business. Owners need to understand their role in the transition process up front and the strategy for the new organization.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.